Cardiovascular Diseases Clinical Trial
Official title:
Evaluate the Safety and Efficacy of the Aventus Thrombectomy System for Aspiration Thrombectomy in Subjects With Acute Pulmonary Embolism
NCT number | NCT05907564 |
Other study ID # | CT-0001 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | September 20, 2023 |
Est. completion date | March 2025 |
Evaluate the safety and efficacy of the Aventus Thrombectomy System for aspiration thrombectomy in subjects with acute pulmonary embolism.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | March 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age = 18 and = 80 years 2. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures 3. Subject is willing and able to comply with all protocol required follow-up visits 4. PE symptom(s) duration = 14 days from index procedure 5. PE diagnosis = 48 hours prior to index procedure 6. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery based on Investigator determination) 7. CTA evidence of dilated RV with an RV/LV ratio of = 0.9 at baseline based on Investigator determination 8. Systolic blood pressure = 90 mmHg without need for vasopressors (initial SBP may be = 80 mmHg if the pressure recovers to = 90 mmHg with intravenous fluids prior to index procedure) 9. Stable heart rate < 130 BPM prior to index procedure 10. Subject is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment Exclusion Criteria: 1. Prior PE = 180 days from index procedure 2. Current hospitalization for other condition(s) 3. Thrombolytic use = 14 days of baseline CTA 4. Pulmonary hypertension with peak pulmonary artery systolic pressure > 70 mmHg by right heart catheterization 5. FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90% 6. Hematocrit < 28% within 6 hours of index procedure 7. Platelets < 100,000/µL 8. Serum creatinine > 1.8 mg/dL 9. International normalized ratio (INR) > 3 10. Presence of intracardiac lead in the right ventricle or right atrium placed < 180 days prior to index procedure 11. Cardiovascular or pulmonary surgery = 7 days prior to index procedure 12. Actively progressing cancer treated by chemotherapeutics 13. Known bleeding diathesis or coagulation disorder 14. Left bundle branch block 15. History of severe or chronic pulmonary arterial hypertension 16. History of chronic left heart disease with left ventricular ejection fraction = 30% 17. History of uncompensated heart failure 18. History of underlying lung disease that is oxygen dependent 19. History of chest irradiation 20. History of heparin-induced thrombocytopenia (HIT) 21. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants 22. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated 23. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for aspiration thrombectomy intervention such as the inability to navigate to target location, predominantly chronic clot or non-clot embolus 24. Life expectancy of < 90 days, as determined by Investigator 25. Female who is pregnant or nursing 26. Current participation in another investigational drug or device treatment study that has not reached the primary endpoint or the Investigator feels would impact their ability to participate in this clinical trial 27. Subject has known residual Iliac Deep Vein Thrombosis (DVT), Inferior Vena Cava (IVC) clot or clot in transit (right atrium and/or right ventricular) 28. Subject on extracorporeal membrane oxygenation (ECMO) |
Country | Name | City | State |
---|---|---|---|
United States | Ascension Seton | Austin | Texas |
United States | Northwestern University | Chicago | Illinois |
United States | University Hospitals | Cleveland | Ohio |
United States | OhioHealth Research Institute | Columbus | Ohio |
United States | Alexian Brothers Medical Center | Elk Grove Village | Illinois |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Ascension St. Vincent | Indianapolis | Indiana |
United States | MemorialCare | Long Beach | California |
United States | Centennial Medical Center (HCA) | Nashville | Tennessee |
United States | CentraCare Heart and Vascular | Saint Cloud | Minnesota |
United States | Honor Health | Scottsdale | Arizona |
United States | Ascension Providence | Southfield | Michigan |
United States | Holy Name Medical Center | Teaneck | New Jersey |
United States | ProMedica - Jobst Vascular | Toledo | Ohio |
United States | Ascension St. John | Tulsa | Oklahoma |
United States | Medstar | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Inquis Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in RV/LV Ratio | Change in RV/LV Ratio per CTA | From Baseline to 48 hours | |
Primary | Major Adverse Event Rate | Composite of device related MAEs including death, major bleed, clinical deterioration, pulmonary vascular injury, and cardiac injury | From Index Procedure to 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|